Search research articles
Contact Us
Filters
Showing results (1-10 of 153) with videos related to
Page
of 16
Sort By:
Case Reports in Medicine
|
October 15, 2009
Profound muscle weakness and pain after one dose of actonel
Irina Badayan, Merit E Cudkowicz
Neurology
|
March 24, 2010
CSF markers in amyotrophic lateral sclerosis: has the time come?
Merit E Cudkowicz, Michael Swash
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases
|
September 27, 2008
Is it too soon for mesenchymal stem cell trials in people with ALS?
Irina Badayan, Merit E Cudkowicz
The New England Journal of Medicine
|
December 2, 2020
Sodium Phenylbutyrate-Taurursodiol for ALS. Reply
Sabrina Paganoni, Merit E Cudkowicz
Annals of Neurology
|
April 28, 2022
Regulatory Approval in ALS; When Is a Single Study Enough?
Merit E Cudkowicz, Jeremy M Shefner
Frontiers of Neurology and Neuroscience
|
May 30, 2009
Clinical trials in progressive neurological diseases. Recruitment, enrollment, retention and compliance
Richard S Bedlack, Merit E Cudkowicz
Journal of Clinical Pharmacology
|
November 18, 2005
Clinical trials in amyotrophic lateral sclerosis: the tenuous past and the promising future
Rabia B Choudry, Merit E Cudkowicz
Annals of Neurology
|
June 18, 2024
Failures to Replicate: What Recent Negative Phase 3 Trials Have Taught Us about Amyotrophic Lateral Sclerosis Clinical Research
Jeremy M Shefner, Merit E Cudkowicz
Neurology
|
May 3, 2014
Locked in, but not out?
Leigh R Hochberg, Merit E Cudkowicz
Biochimica Et Biophysica Acta
|
May 23, 2006
Translating preclinical insights into effective human trials in ALS
Allitia B DiBernardo, Merit E Cudkowicz
Page
of 16
Search research articles
Search
Showing results (1-10 of 153) with videos related to
Sort By:
Page
of 16
Case Reports in Medicine
|
October 15, 2009
Profound muscle weakness and pain after one dose of actonel
Irina Badayan, Merit E Cudkowicz
Neurology
|
March 24, 2010
CSF markers in amyotrophic lateral sclerosis: has the time come?
Merit E Cudkowicz, Michael Swash
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases
|
September 27, 2008
Is it too soon for mesenchymal stem cell trials in people with ALS?
Irina Badayan, Merit E Cudkowicz
The New England Journal of Medicine
|
December 2, 2020
Sodium Phenylbutyrate-Taurursodiol for ALS. Reply
Sabrina Paganoni, Merit E Cudkowicz
Annals of Neurology
|
April 28, 2022
Regulatory Approval in ALS; When Is a Single Study Enough?
Merit E Cudkowicz, Jeremy M Shefner
Frontiers of Neurology and Neuroscience
|
May 30, 2009
Clinical trials in progressive neurological diseases. Recruitment, enrollment, retention and compliance
Richard S Bedlack, Merit E Cudkowicz
Journal of Clinical Pharmacology
|
November 18, 2005
Clinical trials in amyotrophic lateral sclerosis: the tenuous past and the promising future
Rabia B Choudry, Merit E Cudkowicz
Annals of Neurology
|
June 18, 2024
Failures to Replicate: What Recent Negative Phase 3 Trials Have Taught Us about Amyotrophic Lateral Sclerosis Clinical Research
Jeremy M Shefner, Merit E Cudkowicz
Neurology
|
May 3, 2014
Locked in, but not out?
Leigh R Hochberg, Merit E Cudkowicz
Biochimica Et Biophysica Acta
|
May 23, 2006
Translating preclinical insights into effective human trials in ALS
Allitia B DiBernardo, Merit E Cudkowicz
Page
of 16